Company / PP&E (Net)
Trevi Therapeutics, Inc. PP&E (Net) History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$157.0K
FY2024
5-year range
$53.0K / $216.0K
FY2020-FY2024
Trend
-27.3%
vs FY2023
Sector context
#183 of 193
Health Care
What the data says
Among 193 Health Care companies, Trevi Therapeutics, Inc. is in the bottom 5% for pp&e (net). Declined from $170,000 to $157,000 over the past 2 years.
Based on SEC 10-K filings.
$157,000 in FY2024 with a 5-year CAGR of +5.9%.
Declined from $170,000 to $157,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +43.6%
- 5-Year CAGR
- +5.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 193This company $157.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.9%, indicating consistent growth.
- In FY2024, pp&e (net) decreased 27.3% year-over-year.
- Ranks #183 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $157.0K | -27.3% |
| FY2023 | $216.0K | +27.1% |
| FY2022 | $170.0K | +220.8% |
| FY2021 | $53.0K | -48.5% |
| FY2020 | $103.0K | -12.7% |
| FY2019 | $118.0K | -20.8% |
| FY2018 | $149.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026